July 6, 2018 / 5:46 AM / a year ago

ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 (Reuters) - ObsEva, a Switzerland-based drug development company, said on Friday it is keen on a secondary listing on the SIX Swiss Exchange in Zurich, with a trading debut on July 13, as the firm seeks to gain more notice from European investors.

Geneva-based ObsEva, founded by gynecologist and former Serono drug developer Ernest Loumaye, trades on the Nasdaq after selling shares in 2017 and has a market capitalisation of about $658 million.

Since falling below $6 per share in June 2017, its stock has more than doubled in value and traded at $15.13 on Thursday. (Reporting by John Revill and John Miller, Editing by Sherry Jacob-Phillips)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below